March 8, 2017
CTI Clinical Trial and Consulting Services Collaborates with Cardiovascular Systems, Inc. To Improve Healthcare Policy
New Study Finds Substantial Racial and Ethnic Disparities in Amputation Rates Associated with Peripheral Artery Diseases
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ March 8, 2017]
CTI Clinical Trial and Consulting Services (CTI) has collaborated with Cardiovascular Systems, Inc. (CSI360), a large medical device company, to improve healthcare policy.
“This was an incredible series of projects and our team really enjoyed working with Cardiovascular Systems. We shared similar goals and timelines to develop an important research platform which generated evidence that could significantly improve the outcomes of patients with peripheral artery disease and potentially salvage limbs that would be amputated per standard practice.” says Lynn Fallon, CTI President.
A new study published in the Journal of Racial and Ethnic Health Disparities, “Explaining Racial Disparities in Amputation Rates for the Treatment of Peripheral Artery Disease (PAD) using Decomposition Methods,” concludes that compared to Caucasians, African-Americans and Hispanics have less access to limb saving PAD procedures because they are being admitted to the hospital for treatment much later in the disease process and more likely on an emergency basis. However, disease severity and hospital admission through the emergency department only account for half of amputation disparity rates for African-Americans and just 30 percent for Hispanics. The study points to the possibility that minority populations are being systemically treated differently in terms of amputation rates. As the population ages and comorbidities rise, these disparities may accelerate unless access among minorities improves.
According to Bryan T. Fisher Sr., MD, Chief of Vascular Surgery and Co-Director of the Center for Limb Preservation – Tristar Centennial Medical Center, “These factors reflect less access to care overall. Patients who have less access will generally present in worse health and are more likely to go to the ED for their care. Unfortunately, less access translates into substantially different treatment patterns in minorities with PAD, resulting in much higher amputation rates.”
Harry Kotlarz, Cardiovascular Systems, stated, “Our collaborative efforts with CTI are aimed at improving health policy to raise awareness and reduce disparities in amputation rates among minorities. We trust and rely on the CTI Health Economics and Outcomes Research Team, led by Dr. Candace Gunnarsson to generate the high quality evidence that supports our publication strategy.”
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com